Trials / Terminated
TerminatedNCT03773055
Phase II Clinical Trial of NPC-06 in Patients With Neuropathic Pain in Cancer
A Multicenter, Double-blind, Randomized, Placebo-controlled Parallel Group Trial to Investigate the Proof of Concept of NPC-06 in Patients With Neuropathic Pain in Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Nobelpharma · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to investigate the efficiency of pain relief and the safety of NPC-06 for the neuropathic pain associated with cancer, in addition to explore the effective concentration of NPC-06.
Detailed description
The eligible patients will be randomized into three groups, and will receive NPC-06 (high dose), NPC-06 (low dose) or placebo once a day for 7 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NPC-06 | Patients will receive once a day for 7 days. |
Timeline
- Start date
- 2019-04-03
- Primary completion
- 2020-09-30
- Completion
- 2020-09-30
- First posted
- 2018-12-12
- Last updated
- 2020-11-16
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03773055. Inclusion in this directory is not an endorsement.